v3.26.3
Segment Information - Research and development costs and an allocation of indirect research and development costs to each program (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Segment Information        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Total R&D Expense $ 67,407 $ 62,931 $ 207,950 $ 169,741
Single reportable segment        
Segment Information        
Total R&D Expense 67,407 62,931 207,950 169,741
Single reportable segment | Barzolvolimab/Anti-KIT Program        
Segment Information        
Total R&D Expense 53,517 51,619 170,627 133,967
Single reportable segment | CDX-622        
Segment Information        
Total R&D Expense 3,794 5,617 11,590 14,906
Single reportable segment | Other Programs        
Segment Information        
Total R&D Expense $ 10,096 $ 5,695 $ 25,733 $ 20,868